Hedge funds cut NFLX, keep big bets on MSFT, AMZN, add NVDA
Jeff Cislini, the General Counsel at Revolution Medicines, Inc. (NASDAQ:RVMD), a biotechnology company currently valued at $7.09 billion, recently sold a portion of the company’s common stock. According to InvestingPro analysis, the stock is trading near its Fair Value, with analysts setting price targets between $59 and $87. According to a Form 4 filing with the Securities and Exchange Commission, Cislini sold 1,458 shares on March 17, 2025, at an average price of $39.04 per share. This transaction totaled approximately $56,920. The company maintains a strong financial position with more cash than debt and a healthy current ratio of 14.2.
Following the sale, Cislini retains ownership of 59,764 shares, which includes 54,195 restricted stock units. The transaction was conducted under a Rule 10b5-1 instruction letter, which Cislini adopted on May 31, 2023, to cover tax obligations related to vesting restricted stock units. For comprehensive insider trading analysis and additional financial insights, explore the detailed Pro Research Report available on InvestingPro.
In other recent news, Revolution Medicines reported a net loss of $194.6 million for the fourth quarter of 2024, an increase from $161.5 million in the same quarter of the previous year. Despite this, the company maintains a robust cash position of $2.3 billion, bolstered by $823 million from an equity offering. Analysts at H.C. Wainwright have raised the price target for Revolution Medicines to $73, maintaining a Buy rating, while Needham has adjusted its target to $59, also maintaining a Buy rating. The adjustments follow Revolution’s earnings report, which revealed a larger-than-expected loss per share of $1.12, attributed to increased research and development expenses.
Revolution Medicines plans to initiate two additional registrational trials for its investigational drug daraxonrasib, targeting pancreatic ductal adenocarcinoma (PDAC) in earlier treatment lines. These trials are expected to commence in the second half of 2025. H.C. Wainwright projects a net loss of $4.51 per share for Revolution in 2025, citing the company’s strong financial standing as a support for ongoing operations and significant data catalysts through 2027. Meanwhile, Needham anticipates a positive market response to the expansion of daraxonrasib’s trials, particularly in the adjuvant setting for resectable PDAC. Investors are advised to watch for forthcoming clinical data on zoldonrasib as a monotherapy and in combination therapy, anticipated in 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.